ES2152272T3 - Uso de sulodexide y de medicamentos que lo contienen para el tratamiento de la nefropatia diabetica. - Google Patents

Uso de sulodexide y de medicamentos que lo contienen para el tratamiento de la nefropatia diabetica.

Info

Publication number
ES2152272T3
ES2152272T3 ES94107051T ES94107051T ES2152272T3 ES 2152272 T3 ES2152272 T3 ES 2152272T3 ES 94107051 T ES94107051 T ES 94107051T ES 94107051 T ES94107051 T ES 94107051T ES 2152272 T3 ES2152272 T3 ES 2152272T3
Authority
ES
Spain
Prior art keywords
diabetic
nefropatia
treatment
sulodexide
sulodoxide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES94107051T
Other languages
English (en)
Inventor
Egidio Marchi
Gianfranco Tamagnone
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Alfa Wasserman SpA
Original Assignee
Alfa Wasserman SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alfa Wasserman SpA filed Critical Alfa Wasserman SpA
Application granted granted Critical
Publication of ES2152272T3 publication Critical patent/ES2152272T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/727—Heparin; Heparan
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/37—Digestive system
    • A61K35/38—Stomach; Intestine; Goblet cells; Oral mucosa; Saliva
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Abstract

EL USO DE SULODOXIDO, UN GLUCOSAMINOGLUCANO DE ORIGEN NATURAL EXTRAIDO DE MUCOSA INTESTINAL DE MAMIFERO, Y DE MEDICINAS QUE LO CONTIENEN EN EL TRATAMIENTO DE PACIENTES QUE SUFREN DE NEFROPATIA DE ORIGEN DIABETICO CONSTITUYE EL OBJETO DE LA PRESENTE INVENCION. LA EFECTIVIDAD DE SULODOXIDO SE HA DEMOSTRADO POR EL DECRECIMIENTO SIGNIFICATIVO DE ALBUMINURIA EN PACIENTES DIABETICOS DE MICROALBUMINURIA Y MACROALBUMINURIA TRATADA CON COMPOSICIONES FARMACEUTICAS ADMINISTRADAS POR RUTA ORAL O INTRAMUSCULAR QUE CONTIENEN CANTIDADES TERAPEUTICAMENTE EFECTIVAS DE DROGA.
ES94107051T 1993-05-10 1994-05-05 Uso de sulodexide y de medicamentos que lo contienen para el tratamiento de la nefropatia diabetica. Expired - Lifetime ES2152272T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
ITBO930205A IT1270846B (it) 1993-05-10 1993-05-10 Uso di sulodexide e delle specialita' medicinali che lo contengono nel trattamento della nefropatia diabetica.

Publications (1)

Publication Number Publication Date
ES2152272T3 true ES2152272T3 (es) 2001-02-01

Family

ID=11339016

Family Applications (1)

Application Number Title Priority Date Filing Date
ES94107051T Expired - Lifetime ES2152272T3 (es) 1993-05-10 1994-05-05 Uso de sulodexide y de medicamentos que lo contienen para el tratamiento de la nefropatia diabetica.

Country Status (12)

Country Link
US (1) US5496807A (es)
EP (1) EP0624374B1 (es)
JP (1) JP2702400B2 (es)
KR (1) KR0165567B1 (es)
AT (1) ATE198278T1 (es)
CA (1) CA2120062C (es)
DE (1) DE69426471T2 (es)
DK (1) DK0624374T3 (es)
ES (1) ES2152272T3 (es)
GR (1) GR3035231T3 (es)
IT (1) IT1270846B (es)
PT (1) PT624374E (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1274351B (it) * 1994-10-06 1997-07-17 Alfa Wassermann Spa Uso di alcuni glicosaminoglicani nella dialisi peritoneale.
IT1299969B1 (it) * 1998-04-15 2000-04-04 Alfa Wassermann Spa Uso di sulodexide e delle specialita' medicinali che lo contengono nel trattamento della retinopatia diabetica.
IL127896A0 (en) * 1998-12-31 1999-10-28 Gail Laster A novel treatment for preeclampsia and related diseases
US7259152B2 (en) * 2000-06-07 2007-08-21 Alfa Wasserman, Inc. Methods and compositions using sulodexide for the treatment of diabetic nephropathy
WO2002100417A2 (en) * 2001-06-12 2002-12-19 Keryx Biopharmaceuticals Inc. Use of glycosaminoglycans for the treatment of hiv-associated nephropathy
EP1804810A4 (en) * 2004-10-01 2008-02-27 Keryx Biopharmaceuticals Inc METHODS OF TREATING RENALE DISEASE USING GLYCOSAMINOGLYCANS
WO2006082643A1 (ja) 2005-02-03 2006-08-10 Taiyo Kagaku Co., Ltd. 糖尿病および／または糖尿病性腎症の予防、改善、または治療用組成物
WO2006121853A1 (en) * 2005-05-05 2006-11-16 Keryx Biopharmaceuticals, Inc. Combination therapy with sulodexide and a blood pressure reducing agent in the treatment of diabetic nephropathy
DE602006016990D1 (de) * 2005-12-22 2010-10-28 Bellus Health Int Ltd Behandlung von diabetischer nephropathie
KR20090035581A (ko) * 2006-08-04 2009-04-09 아지노모토 가부시키가이샤 신장 기능 장해 예방ㆍ치료제
WO2008070778A2 (en) * 2006-12-06 2008-06-12 Nephrogenex Inc. Pyridoxamine and low molecular weight heparinoids for diabetic kidney disease
EP2120905A1 (en) * 2006-12-22 2009-11-25 BELLUS Health (International) Limited Methods, compounds, and compositions for treating metabolic disorders and diabetes
CN101632686A (zh) * 2008-04-04 2010-01-27 马斯特里赫特大学 糖胺聚糖用于修复糖萼的用途
SG175855A1 (en) 2009-05-04 2011-12-29 Prometic Biosciences Inc Substituted aromatic compounds and pharmaceutical uses thereof
NZ610853A (en) 2010-10-27 2015-05-29 Prometic Biosciences Inc Phenylketone carboxylate compounds and pharmaceutical uses thereof
JP7357948B2 (ja) 2018-07-13 2023-10-10 ユニヴァーシティー オブ マイアミ 腎臓障害を治療するための方法
US20200085810A1 (en) 2018-07-26 2020-03-19 Hoffmann-La Roche Inc. Compounds for use in treating kidney disorders

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1245761B (it) * 1991-01-30 1994-10-14 Alfa Wassermann Spa Formulazioni farmaceutiche contenenti glicosaminoglicani assorbibili per via orale.
IT1245907B (it) * 1991-05-17 1994-10-25 Alfa Wassermann Spa Uso dei glicosaminoglicani nel trattamento della nefropatia diabetica e della neuropatia diabetica.

Also Published As

Publication number Publication date
KR0165567B1 (ko) 1999-01-15
JP2702400B2 (ja) 1998-01-21
PT624374E (pt) 2001-04-30
DE69426471T2 (de) 2001-05-03
DK0624374T3 (da) 2001-01-29
GR3035231T3 (en) 2001-04-30
EP0624374A1 (en) 1994-11-17
CA2120062C (en) 1999-05-25
ITBO930205A1 (it) 1994-11-10
EP0624374B1 (en) 2000-12-27
DE69426471D1 (de) 2001-02-01
CA2120062A1 (en) 1994-11-11
ATE198278T1 (de) 2001-01-15
ITBO930205A0 (it) 1993-05-10
IT1270846B (it) 1997-05-13
JPH06329541A (ja) 1994-11-29
US5496807A (en) 1996-03-05

Similar Documents

Publication Publication Date Title
ES2152272T3 (es) Uso de sulodexide y de medicamentos que lo contienen para el tratamiento de la nefropatia diabetica.
ES2062392T3 (es) Medicamentos que comprenden salmeterol y fluticasona.
BR9407720A (pt) Composto composiçao farmacêutica e processo para a prevençao ou tratamento de pertubaçoes imunorreguladoras ou doenças que compreendem a administraçao do composto
AR004700A1 (es) 1alfa, 26 dihidroxi-d-homo-vitamina d3, una composicion farmaceutica que la comprende, un procedimiento para su preparacion y el uso de los mismos en laelaboracion de un medicamento
IL135335A0 (en) Method for inhibiting or preventing hormone induced adverse effects and novel pharmaceutical compositions comprising carotenoids
AR012998A1 (es) Uso de un sensibilizador a insulina y de un agente antihiperglucemico para la preparacion de un medicamento y composicion farmaceutica que comprende dichosensibilizador y dicho agente.
BR1100776A (pt) Forma de dosagem farmacêutica comprimida e obréia farmacêutica comprimida.
ES2162615T3 (es) Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina.
AR042262A2 (es) Uso de 8,9-dihidroestrona para la preparacion de un medicamento para el tratamiento de aterosclerosis
DE60336806D1 (de) Blister-karte für pharmazeutische behandlung
ATE281171T1 (de) Pharmazeutische zusammensetzung zur immunstimulierenden therapie
AR006401A1 (es) Compuestos de pirrolopirrolona, una composicion farmaceutica que los contiene, su uso en la fabricacion de un medicamento y en terapia, procesospara su preparación y compuestos intermediarios para dichos procesos.
BR9916114A (pt) Uso de apomorfina na fabricação de um medicamento para tratamento de disfunção erétil orgânica masculina
BRPI0415753A (pt) método para tratamento e prevenção da inflamação respiratória com um inibidor de ciclooxigenase-2 em associação com um inibidor de fosfodiesterase 4 e composições que os contêm
AR045144A1 (es) Metodo para tratar a un paciente que tiene un neoplasma o que tiene riesgo de desarrollarlo
BR0313413A (pt) Uso da vacinação beta amilóide juntamente com um inibidor da cox-2 seletivo para o tratamento da doença de alzheimer
BR0211936A (pt) Uso de glicosamina e de um inibidor seletivo para ciclooxigenase-2, ou de pró-droga dos mesmos, na fabricação de um medicamento, bem como composição farmacêutica e kit compreendendo os mesmos
AR030140A1 (es) Composiciones derivadas de la 2-piridinamina y metodos relacionados
BR0017329A (pt) Formulção farmacêutica de um medicamento, uso de melatonina na fabricação de um medicamento, e, método para prevenção ou tratamento de sintomas de discinesia tardia em um paciente usanto tal medicamento
AR011437A1 (es) Composicion farmaceutica para el tratamiento de la migrana y el uso de la misma en la preparacion de un medicamento.
MX9203405A (es) Compuestos activos para usarse en el tratamiento de tumores.
BR0306778A (pt) Derivados de carboxamidina e seu uso no tratamento de doenças vasculares
ES2033181B1 (es) Una tableta o capsula de herbicida para su aplicacion en arrozales.
ES2161809T3 (es) Uso de factor proliferativo osteoblastico.
BRPI0412506A (pt) células autólogas que induzem à autotoleráncia de origem monocìtica e seu uso em preparações farmacêuticos

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 624374

Country of ref document: ES